







A study adds new evidence that SARS-CoV-2—the virus that causes COVID-19—could have a lasting impact on the heart
The CDC whispered this a year ago. “SARS-CoV-2 can have lasting effects on nearly every organ & organ system of the body weeks, months, & potentially years after infection. Documented serious post-Covid conditions include cardiovascular, pulmonary, neurological, renal, endocrin
The CDC whispered this a year ago. “SARS-CoV-2 can have lasting effects on nearly every organ & organ system of the body weeks, months, & potentially years after infection. Documented serious post-Covid conditions include cardiovascular, pulmonary, neurological, renal,… pic.twitter.com/xkSStj51y2— Laura Miers (@LauraMiers) March 9, 2024
SARS-CoV-2 infects coronary arteries, increases plaque inflammation
NIH-funded research sheds light on link between COVID-19 infection and increased risk of cardiovascular disease and stroke.

Evidence mounts that Long Covid is damaging the hearts of those affected
There are also increasing signs that the condition can disrupt the autonomic nervous system

Researchers link Long COVID to another virus | NHK WORLD-JAPAN News
Researchers in Japan have released findings showing that COVID-19 after effects, including fatigue, occur when a coronavirus infection activates another virus already inside the body.
What Are COVID-19’s Long-Term Medical Effects?
Fascinating email from TPM Reader JO, whose personal bio is tailor-made for...

Four ways COVID changed virology: lessons from the most sequenced virus of all time
After 150,000 articles and 17 million genome sequences, what has science taught us about SARS-CoV-2?

COVID-19 Virus Does Not Infect Human Brain Cells, Study Suggests - Slashdot
An anonymous reader quotes a report from The Guardian: The virus that causes Covid-19 does not infect human brain cells, according to a study published in the journal Cell. The findings will raise hopes that the damage caused by Sars-CoV-2 might be more superficial and reversible than previously fea...

Long COVID: How COVID-19 may lead to vicious viral cycle
COVID-19 was linked to the reactivation of several dormant viruses in unvaccinated people, a new study has found. One of the reactivated viruses was also linked to long COVID.

COVID-19 Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season
This Special Communication aims to identify and summarize the most recently published evidence evaluating the effectiveness and safety of US-licensed COVID-19 vaccines and report on the epidemiology of SARS-CoV-2 in the US.

GUESS WHAT?! A new study has shown SARS-CoV-2 infection is DISTINCT from common respiratory viruses! Unequivocally, COVID is NOT "just a cold." These findings are HUGELY significant, for multiple reasons! Here's a breakdown of the study (writt
GUESS WHAT?! A new study has shown SARS-CoV-2 infection is DISTINCT from common respiratory viruses!Unequivocally, COVID is NOT "just a cold."These findings are HUGELY significant, for multiple reasons! Here's a breakdown of the study (written for a general audience)...1/16 pic.twitter.com/P7NJL2STJQ— Nick #RespiratorsFilterAllPathogens😷 Anderegg (@NickAnderegg) July 7, 2024
As of today I ~officially~ have long COVID (as recognized by the CDC), so I wanna take a second to explain what’s happening. To set the stage: I’m 30, I’ve been an athlete my entire life, and I used to be extremely healthy, minus some pesky seasonal allergi
As of today I ~officially~ have long COVID (as recognized by the CDC), so I wanna take a second to explain what’s happening. To set the stage: I’m 30, I’ve been an athlete my entire life, and I used to be extremely healthy, minus some pesky seasonal allergies. My resting heart 1/— Savannah Brooks (on medical leave) (@SBLitAgent) May 22, 2022
COVID-19 Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season
Importance SARS-CoV-2 remains a substantial cause of respiratory illness, morbidity, and mortality. Evidence to date has demonstrated that COVID-19 vaccines reduce the risk of severe disease, including hospitalization and death. Objective This systematic review identifies and summarizes newly published studies reporting on the effectiveness and safety of COVID-19 vaccines and COVID-19 epidemiology in the US. Evidence Review Cochrane Central Register of Controlled Trials, PubMed/MEDLINE, Embase, and Scopus were searched from August 1, 2025, through June 29, 2026. Studies were eligible if they reported on the effectiveness, efficacy, or safety of a US-licensed COVID-19 vaccine or SARS-CoV-2 epidemiology in the US. Findings From 11 829 identified references, 155 publications were eligible (15 randomized clinical trials, 84 observational studies with a comparator group, 38 product safety studies without a comparator group [single group], and 18 descriptive studies of disease burden). Consistent with prior evidence, studies reported that updated COVID-19 vaccines were associated with a reduction in the risk of hospitalization among both older adults (≥65 years; vaccine effectiveness [VE], 53.0%; 95% CI, 37.0%-65.0%; 2025-2026 season) and adults (18-64 years; VE, 54.0%; 95% CI, 1.0%-78.0%; 2024-2025 season). Maternal vaccination was associated with reduced risk of COVID-19–associated emergency department/urgent care encounters among individuals vaccinated (VE, 58.0%; 95% CI, 24.0%-77.0%) and with fewer COVID-19–related hospital contacts in the first 2 months of life among infants born subsequently (VE range, 50.0%-54.0%), regardless of trimester of vaccination. Vaccination was also associated with a significant reduction in COVID-19–related pediatric emergency department visits (9 months to 4 years; VE, 76.0%; 95% CI, 58.0%-87.0%). Vaccination was associated with a reduced risk of critical COVID-19 illness (intensive care unit admission or death) in immunocompromised adults (VE range, 32.0%-53.0%, depending on condition and other factors). Health care personnel who received 3 to 5 vaccine doses were less likely to develop laboratory-confirmed COVID-19 illness (VE, 41.0%; 95% CI, 34.0%-47.0%) and postacute COVID-19 symptoms (VE, 57.0%; 95% CI, 46.0%-66.0%) compared with those who received only 2 doses. Across adverse events of special interest (eg, stroke, thrombosis, myocarditis), safety profiles were consistent with those of previous reviews. No identified studies conducted under the updated guidance on extended dosing intervals for the primary series reported an increased risk of myocarditis or pericarditis. No new safety signals were reported in the recently published studies eligible for this updated review of US-licensed COVID-19 vaccines. Conclusions and Relevance COVID-19 vaccines were consistently associated with a reduction in the risk of hospitalization and other outcomes, including among individuals at high risk of severe COVID-19, such as infants, and those who were pregnant. No new safety concerns were identified.

Current status and future perspectives on the mechanistic and pathophysiological understanding of long COVID
Viral and infectious illnesses can exert profound and enduring effects on population health and well-being. In the aftermath of SARS-CoV-2 infection, post-acute sequelae, collectively referred to as Long COVID, have emerged as a major global health challenge, affecting more than 400 million people and contributing to estimated annual economic costs exceeding $1 trillion. Long COVID encompasses a wide and heterogeneous spectrum of debilitating symptoms, including cognitive dysfunction, sleep disturbances, severe fatigue, and post-exertional malaise. Despite its substantial burden, fundamental uncertainties remain regarding its underlying pathophysiology, the development of robust diagnostic criteria, and the identification of effective therapeutic options. This review synthesises current evidence on the biological mechanisms thought to contribute to Long COVID, spanning immune dysregulation, viral persistence, autonomic dysfunction, microvascular pathology, and other emerging hypotheses. We examine advances and limitations in contemporary diagnostic approaches and critically appraise existing treatment strategies, highlighting inconsistencies and gaps that hinder clinical consensus. By integrating interdisciplinary insights, this review underscores the urgent need for mechanistic clarity, validated diagnostic frameworks, and rigorously evaluated treatment pathways. Addressing these gaps will be essential to developing effective, evidence-based management strategies and mitigating the long-term impact of Long COVID on global health.

Current status and future perspectives on the mechanistic and pathophysiological understanding of long COVID
Viral and infectious illnesses can exert profound and enduring effects on population health and well-being. In the aftermath of SARS-CoV-2 infection, post-acute sequelae, collectively referred to as Long COVID, have emerged as a major global health challenge, affecting more than 400 million people and contributing to estimated annual economic costs exceeding $1 trillion. Long COVID encompasses a wide and heterogeneous spectrum of debilitating symptoms, including cognitive dysfunction, sleep disturbances, severe fatigue, and post-exertional malaise. Despite its substantial burden, fundamental uncertainties remain regarding its underlying pathophysiology, the development of robust diagnostic criteria, and the identification of effective therapeutic options. This review synthesises current evidence on the biological mechanisms thought to contribute to Long COVID, spanning immune dysregulation, viral persistence, autonomic dysfunction, microvascular pathology, and other emerging hypotheses. We examine advances and limitations in contemporary diagnostic approaches and critically appraise existing treatment strategies, highlighting inconsistencies and gaps that hinder clinical consensus. By integrating interdisciplinary insights, this review underscores the urgent need for mechanistic clarity, validated diagnostic frameworks, and rigorously evaluated treatment pathways. Addressing these gaps will be essential to developing effective, evidence-based management strategies and mitigating the long-term impact of Long COVID on global health.

THIS IS HUGE! Researchers at Stanford University have developed a dual-antibody treatment that remains effective against ALL SARS-CoV-2 variants by targeting a less-mutable part of the virus. This breakthrough could lead to longer-lasting therapies that OUTPACE viral evolution. 🧪🧵⬇️
49% of COVID infections are asymptomatic according to Yale School of Public Health. Yale advises layered protection: N95 masks, HEPA filters…
doi.org